SKIN AUTOFLUORESCENCE AND CUMULATIVE METABOLIC BURDEN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Main Article Content
Abstract
Objectives: To investigate the association between skin autofluorescence and obesity in patients with type 2 diabetes mellitus, and to evaluate the respective roles of skin autofluorescence and body mass index in relation to glycemic control and renal function.
Methods: A cross-sectional descriptive study was conducted in 149 patients with type 2 diabetes mellitus. Participants were stratified according to body mass index (< 25 kg/m² and ≥ 25 kg/m²). Skin autofluorescence was measured using the AGE Reader mu device. Clinical and biochemical variables included body mass index, HbA1c, and estimated glomerular filtration rate. Poor glycemic control was defined as HbA1c ≥ 7%.
Results: No significant difference in skin autofluorescence levels was observed between body mass index groups (p > 0.05). Lower body mass index was associated with poor glycemic control (HbA1c ≥ 7%) (OR = 0.89; p < 0.05), suggesting a “lean diabetes” phenotype. In contrast, skin autofluorescence has a correlation with age (r = 0.26; p < 0.01) and has an inverse correlation with estimated glomerular filtration rate (r = -0.31; p < 0.01).
Conclusions: Skin autofluorescence was not associated with obesity status but was related to age and renal function in patients with type 2 diabetes, suggesting a potential role of skin autofluorescence as an additional marker reflecting cumulative metabolic burden.
Article Details
Keywords
Type 2 diabetes mellitus, skin autofluorescence, advanced glycation end-products
References
[2] Rhee S.Y, Kim Y.S. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J, 2018, 42 (3): 188-195. doi: 10.4093/dmj.2017.0105
[3] Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules, 2022, 12 (4): 542. doi: 10.3390/biom12040542.
[4] van Waateringe R.P, Fokkens B.T et al. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. Diabetologia, 2019, 62 (2): 269-280. doi: 10.1007/s00125-018-4769-x.
[5] Monami M, Lamanna C et al. Skin autofluorescence in type 2 diabetes: beyond blood glucose. Diabetes Research and Clinical Practice, 2008, 79 (1): 56-60.
[6] Lutgers H.L, Graaff R et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care, 2006, 29 (12): 2654-9. doi: 10.2337/dc05-2173.
[7] Sánchez E, Sánchez M et al. Is there a link between obesity indices and skin autofluorescence? A response from the ILERVAS project. Nutrients, 2022, 15 (1): 203.
[8] Alkhami F, Borderie G et al. Skin autofluorescence of advanced glycation end-products relates to new cardiovascular events in type 2 diabetes: a longitudinal observational study. Diabetes & Metabolism, 2024, 50 (2): 101524.
[9] Kim J.M, Joung K.H et al. Lean diabetes: 20-year trends in its prevalence and clinical features among Korean adults. BMC Public Health, 2024, 24 (1): 3554.
[10] Smit A.J, Gerrits E.G. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2010, 19 (6): 527-33.